Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin B3 supplement put to the test against psoriasis inflammation

NCT ID NCT04271735

Symptom relief Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing whether nicotinamide riboside, a form of vitamin B3 sold as a supplement, can reduce immune system activation in people with mild to moderate psoriasis. The trial enrolls adults aged 18 to 80 who are not on biologic therapy. Participants take either the supplement or a placebo twice daily for four weeks, and researchers measure changes in specific immune cells and skin inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicotinamide riboside, a form of vitamin B3 taken as a dietary supplement
What this could lead to
If it works, nicotinamide riboside could offer a low-cost supplement option for calming the immune activation that drives psoriasis and related heart risks.
What could go wrong
This is a small pilot study of 29 people taking the supplement for only four weeks. The results may not hold up in larger trials, and the supplement may not change immune activity enough to matter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Aug 2020

Finished

Dec 2022

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Individuals must meet all inclusion criteria listed below in order to be eligible to participate in the study. * Males and females between the ages of 18 and 80 with mild to moderate active psoriasis. * Female subjects of child-bearing ability willing to commit to reliable contraception while participating in the study. * Ability to provide informed consent * Willingness and ability to participate in required study procedures EXCLUSION CRITERIA: * Severe psoriasis by PASI (Psoriasis Area and Severity Index) score \> 12 * Currently being treated with biologic immune modifying agents. * Currently on treatment for allergies or other inflammatory diseases. * Currently taking a multivitamin, Vitamin B or tryptophan supplementation and unwilling to stop within 2 weeks of baseline visit. * Unwillingness/inability to provide informed consent * ALT \> x3 upper limit of normal, hepatic insufficiency or active liver disease * Recent history of acute gout * Chronic renal insufficiency with creatinine \> 2.5mg/dl * Pregnant (or attempting to become pregnant) women * Current participation in another drug study * History of intolerance to NR precursor compounds, including niacin or nicotinamide * Study adherence concerns * Individuals with diabetes type 1 and 2 who use insulin * Women of child-bearing potential unwilling to use contraception or unwilling to practice abstinence * Breastfeeding women unwilling to stop breastfeeding * Immunization administered within 30 days of participation and no plans for immunization while participating in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease Dyslipidemias inherited lipid metabolism disorder Obesity obesity disorder psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerotic cardiovascular disease Cardiometabolic diseases Dyslipidemia Obesity Psoriasis

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.